Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product.
The company says that it will also use the funding “to invest in third-party manufacturers and the supply chain in order to establish redundancy and commercial supply capability in advance of the launch of Arikace in Europe and the United States,” along with “other general corporate purposes.” Those other purposes might include acquisition of additional technology, candidates, or businesses, according to the announcement.
Earlier this month, Insmed announced that Arikace met the primary endpoints in a Phase 3 study in more than 300 CF patients.
Read the Insmed press release.
